For investors seeking intriguing opportunities, exploring the vibrant space of stocks trading under 0.5 cents on the OTC market can offer a compelling journey. These often-overlooked penny stocks might not be on everyone's radar, but for those with a knack for navigating the dynamic OTC landscape, they hold the promise of excitement. With an affordable entry price per share, these micro-cap stocks present a chance to diversify portfolios, potentially supercharging gains if the right companies catch a wave.
Today we'll dive into a selection of some of the more active OTC penny stocks under $.02
Ameritek Ventures (OTC: ATVK)
ATVK is a dynamic emerging technology company that offers a unique foothold in the forefront of cutting-edge industries, such as robotic technology, artificial intelligence, and blockchain cloud software. Anchored by its subsidiary Augmum, the company is effectively positioned to capitalize on the burgeoning potential of augmented reality and machine learning technologies. Augmum's innovative approach merges these transformative technologies to augment the control of robotic arms using gloves and glasses.
Augmum's robotic technology harnesses the power of virtual reality and real-time monitoring, facilitating swift and precise task execution. This revolutionary capability has the potential to revolutionize various industries by replacing manual labor and streamlining operations. As industries increasingly adopt automated solutions, Ameritek Ventures' robotic technology could reshape work processes and contribute to workforce optimization.
The broader implications of this technology are substantial, as it aligns with the company's long-term objective to capture market share and value in the burgeoning robotic technology sector. With the projected growth of the robotic technology market expected to reach $283 billion by 2032 from $72 billion in 2022, Ameritek Ventures is poised to capitalize on this rapidly expanding field.
In a recent milestone, Ameritek Ventures confirmed on June 14, 2023, that its subsidiary, Augmum Inc., is actively developing HaliOas augmented reality glasses integrated with artificial intelligence. These innovative glasses mark a significant advancement, aimed at serving critical functions in the medical, construction, and military industries. The incorporation of artificial intelligence technology enables these glasses to highlight important items for end-users, adding an intuitive layer to their experience.
HaliOas stands as a transformative augmented reality headset, enabling seamless projection of information in the user's field of vision. Its versatile design ensures all-day usability, opening the door to a multitude of applications and use cases. By overlaying virtual information onto the physical world, including functionalities resembling smartphones such as map navigation, the headset offers an immersive experience.
Dr. Shaun Passley, the CEO of Ameritek Ventures, expressed enthusiasm about HaliOas, stating, "It is a high-quality and affordable AR solution that can enhance their experience with our AI-integrated robotic arm technology." The company's commitment to accessibility is evident, as Augmum plans to offer the AI-powered AR headset at a competitive price point below $500. This economic strategy aims to catalyze mass adoption by ensuring widespread accessibility and end-user exploration of the technology's potential.
In conclusion, Ameritek Ventures is pioneering the integration of augmented reality and machine learning with its subsidiary, Augmum. Their concerted efforts to democratize cutting-edge technology through accessible pricing could potentially drive the mass adoption of AI-powered augmented reality solutions, while their core robotic technology positions them to capitalize on the automation revolution. As these innovations continue to unfold, Ameritek Ventures remains at the forefront of shaping the future of technological advancement across diverse industries.
ViaDerma, Inc. (OTC: VDRM)
VDRM is a publicly traded specialty pharmaceutical company dedicated to introducing new products and licensing its innovative transdermal drug delivery technology solutions to established leaders in the pharmaceutical industry across diverse therapeutic areas.
In a notable update on July 6, 2023, ViaDerma shared exciting developments for current and potential stakeholders, partners, and healthcare providers. The company is making substantial strides in its efforts to finalize distribution approvals for its flagship product, Vitastem Ultra, across multiple countries in the Caribbean and the Middle East. The ongoing stability testing process is over 30% complete, with expectations to conclude the required testing protocols by the end of August or early September this year. Simultaneously, ViaDerma's hair regrowth product, Nupelo, is in the final stages of securing FDA-registered product approval. In response to feedback, the company submitted additional information required for final approvals in early June, with imminent anticipation for FDA clearance.
Moreover, ViaDerma is actively engaged in enhancing its manufacturing capabilities. An impending agreement with a larger FDA-registered product manufacturing facility is set to enable the production of over 100,000 units of Vitastem product within a 6-8 week lead time. This step is pivotal in meeting amplified customer demand, both domestically and internationally, following earlier challenges in scalability. By securing a new Tier-1 FDA-registered medical product manufacturer, ViaDerma is well-positioned for successful scaling and satisfying heightened demands from healthcare professionals and distributors.
Additionally, ViaDerma is actively pursuing improved reporting standards. In the process of selecting auditors, CPA firms, and attorneys, the company aims to fulfill the two-year audited financial statement requirement. Successful completion will pave the way for seeking uplisting to the OTCQB.
A landmark achievement in public health, Vitastem Ultra, a potent topical antibiotic spray, is now accessible for purchase online. Previously available primarily through medical professionals, this transformative move expands patient access and aligns with the pressing need for innovative wound care solutions. Vitastem Ultra's efficacy against a broad spectrum of bacterial skin infections, including antibiotic-resistant strains, positions it as a versatile solution for wound care and various skin conditions.
As of August 21, VDRM closed at 0.013 USD, marking a notable increase of 23.81%.
Rennova Health, Inc. (OTC: RNVA)
Rennova Health Inc. is a healthcare services provider with a growing presence. Operating Big South Fork Medical Center in Oneida, Tennessee, and a hospital in Jamestown, Tennessee (planned for reopening), the company also runs a rural clinic in Kentucky. Additionally, through its subsidiary Myrtle Recovery Centers, Inc., Rennova recently opened an alcohol and drug treatment facility at its Big South Fork Medical Center campus.
In an update dated August 21, 2023, CEO Seamus Lagan discussed Rennova's progress after filing the 2023 second quarter financial statements with the SEC. Notable achievements include the successful opening of a mental and behavioral health facility and the filing of the second quarter 10-Q on time. Lagan expressed confidence in the sustainable growth of revenues, emphasizing that a focus on efficient operations and additional services could potentially lead to revenues exceeding $20 million for 2023.
Furthermore, Myrtle Recovery Centers, Inc.'s newly opened 30-bed facility is anticipated to contribute significantly to revenue. Lagan projected that this subsidiary, offering alcohol and substance abuse services, could generate $4-$5 million in profitable revenues annually.
In light of these advancements, Rennova Health envisions an annualized run rate of $25-$30 million by year-end. Lagan revealed a plan to replicate the current model at the Jamestown facility in 2024, potentially resulting in annualized revenues of $50-$60 million by the end of 2024.
Elite Pharmaceuticals, Inc. (OTC: ELTP)
Elite Pharmaceuticals, Inc. is a specialized pharmaceutical company that focuses on the development, manufacturing, and distribution of niche generic products. With a commitment to innovation and effective solutions, this company has become a notable player in the pharmaceutical industry.
The product lines include immediate-release and controlled-release solid oral dose products, marketed under the Elite Laboratories label. These products are distributed through licensing agreements with third-party pharmaceutical marketing and distribution organizations. Operating out of Northvale, NJ, the company runs a registered facility that adheres to stringent quality and safety standards, ensuring the production of high-caliber pharmaceuticals.
In its recent financial report for the first quarter of fiscal year 2024 (ended June 30, 2023), the company demonstrated impressive financial growth. Revenues for the quarter reached $9.0 million, a remarkable increase of 16.9% compared to the same period the previous year. The company's efforts and operational efficiency contributed to this substantial revenue growth.
Operating profits during the same quarter surged to $1.6 million, representing a significant 60% increase from the corresponding period in the prior fiscal year. Additionally, net income attributable to common shareholders stood at $1.1 million, showing an impressive growth of 267% compared to the same quarter of the previous year. This exceptional financial performance underscores the dedication to driving sustainable growth.
Yesterday, ELTP demonstrated strong performance, closing at $0.090 USD per share, marking a gain of 23.79%. This positive movement reflects investor confidence in the company's direction and growth potential.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Ameritek Ventures Inc. to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.
CONTACT: CapitalGainsReport
Mark McKelvie
Editor
Markrmckelvie@gmail.com
585-301-7700
.
AMERITEK VENTURES, INC. 
